Omega Therapeutics, Inc. (OMGA)

NASDAQ: OMGA · IEX Real-Time Price · USD
3.520
-0.100 (-2.76%)
At close: Mar 18, 2024, 4:00 PM
3.481
-0.039 (-1.11%)
After-hours: Mar 18, 2024, 7:50 PM EDT
-2.76%
Market Cap 194.10M
Revenue (ttm) 2.84M
Net Income (ttm) -108.04M
Shares Out 55.14M
EPS (ttm) -2.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 336,154
Open 3.670
Previous Close 3.620
Day's Range 3.450 - 3.670
52-Week Range 1.300 - 10.090
Beta 1.88
Analysts Strong Buy
Price Target 11.75 (+233.81%)
Earnings Date May 2, 2024

About OMGA

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, an... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2021
Employees 116
Stock Exchange NASDAQ
Ticker Symbol OMGA
Full Company Profile

Financial Performance

In 2022, OMGA's revenue was $2.07 million, an increase of 1339.58% compared to the previous year's $144,000. Losses were -$102.70 million, 50.4% more than in 2021.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for OMGA stock is "Strong Buy." The 12-month stock price forecast is $11.75, which is an increase of 233.81% from the latest price.

Price Target
$11.75
(233.81% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024

CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable...

12 days ago - GlobeNewsWire

Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases

Bagsværd, Denmark, Cambridge, Mass., and Somerville, Mass. 4 January, 2024 – Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) and Cellarity Inc. today announced that Novo Nordisk has en...

2 months ago - GlobeNewsWire

Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable ...

2 months ago - GlobeNewsWire

Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable ...

3 months ago - GlobeNewsWire

Omega Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable ...

4 months ago - GlobeNewsWire

Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis

First-ever demonstration of sustained pre-transcriptional upregulation of gene expression by an epigenomic controller in both in vitro and in vivo models of liver fibrosis

4 months ago - GlobeNewsWire

Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable ...

4 months ago - GlobeNewsWire

Omega Therapeutics to Participate in The Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable ...

4 months ago - GlobeNewsWire

Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller

Coordinated modulation of epigenetic profile of CXCL1-8 genes with corresponding downregulation of gene expression and protein levels, and inhibition of immune cell recruitment, shown in multiple mode...

4 months ago - GlobeNewsWire

Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC

Combination of a MYC-targeting epigenomic controller with immune checkpoint or EGFR inhibitor enhanced anti-tumor activity in models of NSCLC Combination of a MYC-targeting epigenomic controller with ...

5 months ago - GlobeNewsWire

Omega Therapeutics Announces Two Poster Presentations on Liver Inflammation and Fibrosis at AASLD's The Liver Meeting® 2023

CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable ...

5 months ago - GlobeNewsWire

Top 4 Health Care Stocks That Are Preparing To Pump This Quarter - Omega Therapeutics (NASDAQ:OMGA), Cutera (NASDAQ:CUTR)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: CUTRRVMDVNRX
5 months ago - Benzinga

Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable ...

5 months ago - GlobeNewsWire

Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial

All 8 patients treated with OTX-2002 in initial two cohorts achieved highly specific on-target genomic engagement, intended epigenetic state change and robust downregulation in expression of c-MYC , a...

6 months ago - GlobeNewsWire

Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable...

6 months ago - GlobeNewsWire

Omega Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable...

6 months ago - GlobeNewsWire

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

CAMBRIDGE, Mass. , Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Developmen...

Other symbols: DNLIFHTXMCRBMRNASANA
6 months ago - PRNewsWire

Omega Therapeutics Announces Updates to its Board of Directors

CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable ...

7 months ago - GlobeNewsWire

Omega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable ...

8 months ago - GlobeNewsWire

Omega Therapeutics Appoints Chris Schade to its Board of Directors

Accomplished Industry Veteran Brings Deep Strategic and Operational Expertise Accomplished Industry Veteran Brings Deep Strategic and Operational Expertise

8 months ago - GlobeNewsWire

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

Empress's Chemilogics™ product platform creates small molecule drugs quickly and cost-effectively The company emerges after two years of platform development with an initial commitment of $50 million ...

Other symbols: DNLIFHTXMCRBMRNASANA
9 months ago - PRNewsWire

Ashvattha Therapeutics Expands Leadership Team with Appointment of Paul E. Cayer as Chief Financial Officer and Mahesh Karande to the Board of Directors

REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers t...

10 months ago - GlobeNewsWire

Omega Therapeutics Presents New Preclinical Data Demonstrating the Potential of Omega Epigenomic Controllers™ to Synergize with Immunotherapies at the ASCO 2023 Annual Meeting

CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable e...

10 months ago - GlobeNewsWire

Omega Therapeutics Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable e...

11 months ago - GlobeNewsWire

Omega Therapeutics to Present New Preclinical Data at the American Society of Clinical Oncology 2023 Annual Meeting

CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable...

11 months ago - GlobeNewsWire